| Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study MJ Overman, R McDermott, JL Leach, S Lonardi, HJ Lenz, MA Morse, ... The lancet oncology 18 (9), 1182-1191, 2017 | 2610 | 2017 |
| Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair–deficient/microsatellite instability–high metastatic colorectal cancer MJ Overman, S Lonardi, KYM Wong, HJ Lenz, F Gelsomino, M Aglietta, ... Journal of clinical oncology 36 (8), 773-779, 2018 | 1947 | 2018 |
| Activation of the receptor for advanced glycation end products triggers a p21 ras-dependent mitogen-activated protein kinase pathway regulated by oxidant stress HM Lander, JM Tauras, JS Ogiste, O Hori, RA Moss, AM Schmidt Journal of Biological Chemistry 272 (28), 17810-17814, 1997 | 929 | 1997 |
| Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience RL Fine, AP Gulati, BA Krantz, RA Moss, S Schreibman, DA Tsushima, ... Cancer chemotherapy and pharmacology 71, 663-670, 2013 | 260 | 2013 |
| Nivolumab±ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 … MJ Overman, S Kopetz, RS McDermott, J Leach, S Lonardi, HJ Lenz, ... Journal of Clinical Oncology 34 (15_suppl), 3501-3501, 2016 | 166 | 2016 |
| First-in-human clinical trial of oral ONC201 in patients with refractory solid tumors MN Stein, JR Bertino, HL Kaufman, T Mayer, R Moss, A Silk, N Chan, ... Clinical cancer research 23 (15), 4163-4169, 2017 | 150 | 2017 |
| Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028. PA Ott, MEE Fernandez, S Hiret, DW Kim, RA Moss, T Winser, S Yuan, ... Journal of Clinical Oncology 33 (15_suppl), 7502-7502, 2015 | 126 | 2015 |
| Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National Center for Health Statistics Database KJ Yao, S Jabbour, N Parekh, Y Lin, RA Moss BMC gastroenterology 16, 1-8, 2016 | 105 | 2016 |
| Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142. MJ Overman, S Lonardi, F Leone, RS McDermott, MA Morse, KYM Wong, ... Journal of Clinical Oncology 35 (4_suppl), 519-519, 2017 | 83 | 2017 |
| Clinical actionability of comprehensive genomic profiling for management of rare or refractory cancers KM Hirshfield, D Tolkunov, H Zhong, SM Ali, MN Stein, S Murphy, H Vig, ... The oncologist 21 (11), 1315-1325, 2016 | 79 | 2016 |
| Intensity‐Modulated Radiation Therapy for Rectal Carcinoma Can Reduce Treatment Breaks and Emergency Department Visits SK Jabbour, S Patel, JM Herman, A Wild, SN Nagda, T Altoos, ... International Journal of Surgical Oncology 2012 (1), 891067, 2012 | 75 | 2012 |
| Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies R Salgia, P Patel, J Bothos, W Yu, S Eppler, P Hegde, S Bai, S Kaur, ... Clinical Cancer Research 20 (6), 1666-1675, 2014 | 72 | 2014 |
| Nivolumab+ ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report … T Andre, S Lonardi, M Wong, HJ Lenz, F Gelsomino, M Aglietta, M Morse, ... Journal of Clinical Oncology 36 (4_suppl), 553-553, 2018 | 69 | 2018 |
| A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG–ACRIN Cancer Research Group (E2511) TK Owonikoko, SE Dahlberg, SA Khan, DE Gerber, J Dowell, RA Moss, ... Lung Cancer 89 (1), 66-70, 2015 | 67 | 2015 |
| Chemotherapy-induced-peripheral neuropathy, gait and fall risk in older adults following cancer treatment TF Marshall, GP Zipp, F Battaglia, R Moss, S Bryan Journal of Cancer Research and Practice 4 (4), 134-138, 2017 | 66 | 2017 |
| A blueprint to advance colorectal cancer immunotherapies DT Le, VM Hubbard-Lucey, MA Morse, CR Heery, A Dwyer, TH Marsilje, ... Cancer immunology research 5 (11), 942-949, 2017 | 66 | 2017 |
| Temozolomide/capecitabine therapy for metastatic neuroendocrine tumors of the pancreas. A retrospective review WH Isacoff, RA Moss, AL Pecora, RL Fine Journal of Clinical Oncology 24 (18_suppl), 14023-14023, 2006 | 60 | 2006 |
| Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): long-term survival according to prior … MJ Overman, F Bergamo, RS McDermott, M Aglietta, F Chen, ... Journal of Clinical Oncology 36 (4_suppl), 554-554, 2018 | 54 | 2018 |
| Phase I trial of veliparib,(ABT-888), a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors. AR Tan, D Toppmeyer, MN Stein, RA Moss, M Gounder, DC Lindquist, ... Journal of Clinical Oncology 29 (15_suppl), 3041-3041, 2011 | 47 | 2011 |
| Non-operative therapies for colorectal liver metastases JL Nosher, I Ahmed, AN Patel, V Gendel, PG Murillo, R Moss, SK Jabbour Journal of gastrointestinal oncology 6 (2), 224, 2015 | 45 | 2015 |
Thierry AndréHôpital Saint Antoine在 aphp.fr 的电子邮件经过验证
